not used title

not used title

This June marks Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride Month. At PhRMA, we’re proud to celebrate the diversity and inclusion of our LGBTQ+ colleagues and the patients our companies aim to help. As an industry driven by science, we believe diversity in the lab drives greater collaboration, scientific advancement and groundbreaking medicines impacting the lives of patients.

PhRMA is proud to have an employee resource group (ERG), The PRIDE Umbrella, which seeks to build a stronger culture, professional development and awareness of LGBTQ+ employees at PhRMA and welcome allies along the way.  Under the leadership of the group’s co-chairs Dharia McGrew and John Nappi, the ERG is hosting educational events, social networking and raising funds for LGBTQ+ charities all month long.

Dharia and John recently reached out to PhRMA member companies to learn more about how some of them are supporting LGBTQ+ employees within their companies and the patients they aim to impact with advancements in medicine.

Alkermes
Alkermes is committed to taking actions, both big and small, that continue to demonstrate our steadfast commitment to the LGBTQ+ community. In 2022, in addition to celebrating observances like Pride Month and hosting events for employees to hear directly from LGBTQ+ leaders, we provided financial support to groups like OutBio, PFLAG, BeLong To and others in recognition of their efforts to advocate for and support LGBTQ+ equality across the United States and Ireland. Pride@Work, our employee resource group for LGBTQ+ employees and allies will continue to guide our work in this space in 2023 and beyond as we work to ensure employees at Alkermes feel able to bring their authentic selves to work every day.

Amgen
Amgen, one of the world’s leading biotech companies, is committed to building a diverse and inclusive workforce where employees feel a sense of belonging and can bring their whole selves to work. We recognize the significance and importance of LGBTQ+ rights, and at Amgen we are committed to inclusive practices that support and provide resources to our employees who are part of this community.  Amgen has been ranked as a Best Place to Work for LGBTQ+ Equality by the Human Right’s Campaign’s (HRC) Corporate Equality Index for seven consecutive years. Amgen has modernized language in our HR policies and guidelines to be more inclusive of employees who are transgender, gender non-conforming/nonbinary, or intersex (TGI), including by addressing considerations for transitioning at work. We do this because we believe that our differences lead to better science and all employees, including members of the LGBTQ+ community, are an asset in strengthening our global workforce and supporting our mission to serve patients.

Astellas
In collaboration with a very active LGBTQ+ Employee Impact Group and an engaged and visibly supportive Executive Committee, Astellas US has provided equal health care and benefits to the LGBTQ+ community as with all other employees for several years; our health care benefits are widely considered industry leading. We provide family building and parenting support services for non-traditional families. To better support mental health, we have formally introduced a policy respecting individuals who transition genders and support all gender identities.

Biogen
Biogen fosters a welcoming workplace for LGBTQ+ employees and their allies through the execution of inclusive programming, events, and advocacy. In recognition of Pride Month, we will raise the rainbow flag at our locations, participate in global pride parades, and hold programs at our affiliates around the world. We will also highlight the story of an employee who is undergoing gender-affirming care with the aspiration of raising awareness and understanding for the transgender experience and how Biogen supports a culture of belonging.

Bristol Myers Squibb
Bristol Myers Squibb (BMS) leads with its Value of Inclusion by creating a company culture that enables our LGBTQ+ colleagues to bring their authentic selves to the workplace, instituting progressive workplace policies and benefits and enabling ally education. BMS and our PRIDE Alliance People & Business Resource Group (PBRG) are proud to support the LGBTQ+ community by making meaningful investments to support LGBTQ+ health equity.

CSL
At CSL as part of our promising future, we are fostering an inclusive culture with training for all employees to explore the concepts behind LGBTQIA+ identity, the workplace issues members of the community face, and how to be an ally to support inclusion and a sense of belonging for all. We have also engaged colleagues to share their perspectives and experiences in a video to raise awareness and widen views. We support our employees by including domestic partners in company health care benefits as well as our caregiver, parental and bereavement leave policies; last year we added coverage of family forming benefits and expanded gender affirmation coverage, and this year we implemented Lyra mental health benefits which has specialists with LGBTQ experience.

Daiichi Sankyo 
As Daiichi Sankyo seeks to fulfill its purpose to create new standards of care, we are committed to an inclusive and diverse organization as well as a culture of equity and belonging that fuels exceptional value for patients, our employees and business. Our employee benefits programs provide for the unique needs of our diverse employees, including the LGBTQ+ population. Every June, we recognize Pride month around the globe by celebrating stories from our LGBTQ+ employees and allies and raising the rainbow flag in our office buildings in solidarity. As part of our inclusive business practices, we must ensure that our clinical trials are available to a diverse range of patients and that the demographics of our studies reflect the real-world demographics of a given condition.

EMD Serono
At EMD Serono, as well as at MilliporeSigma and EMD Electronics, our life science and electronics businesses in the U.S., our company will be participating in four Pride parades across the country to support our LGBTQ+ employees and allies. Additionally, our Rainbow Network employee resource group will host several internal events discussing LGBTQ+ topics, including LGBTQ+ parenting and families, and the intersectionality of Multiple Sclerosis and the LGBTQ+ patient population. We also will continue to bring awareness internally to the LGBTQ+-inclusive benefits our company offers, particularly gender affirming services and family planning programs.

Genentech 
Genentech has long supported LGBTQ+ rights within and beyond our walls – from being one of the first companies to extend benefits coverage to employees’ same-sex domestic partners in 1994 to partnering with a wide array of organizations advocating for the inclusive and equitable treatment of LGBTQ+  communities and patients. We have been recognized by the Human Rights Campaign Foundation as one of the best places to work for LGBTQ+ employees, earning a top score of 100 in their Corporate Equality Index for 16 consecutive years. This is a reflection of our commitment to sustaining an environment in which employees can show up as their authentic selves regardless of sexual orientation or gender identity. By addressing the unique needs of our LGBTQ+ employees, we are fostering a culture of belonging for all of our employees to thrive.

Gilead
Gilead’s decades-long history of advancing health care for the LGBTQ+ community includes our pioneering research and development of therapies for HIV, which continues to disproportionately impact this community, with the ultimate goal of ending the epidemic for everyone, everywhere. Gilead is also committed to partnering with LGBTQ+ advocacy organizations to address HIV and emerging threats facing the LGBTQ+ community. Equally Gilead has a deep commitment to improving health equity and reducing stigma associated with HIV, such as supporting community organizations serving those most impacted by HIV and working to improve access to care — including those in the U.S. South where HIV is most prevalent, and through Gilead’s TRANScend Community Impact Fund, aimed at improving the safety, health and wellness of the transgender community.

GSK
GSK’s LGBTQ+ Employee Resource Group (ERG), Spectrum, has a 25+ year reputation of advancing LGBTQ+ inclusion through advocacy and activism. Leveraging impactful speaker series, awareness campaigns; and insights related to social issues that impact the LGBTQ+ community, it offers year-round thought-leadership and educational resources that serve as catalysts to activate allies and remove barriers to access to health care. The work of the ERG is vital to ensuring everyone receives access to equitable treatment; free of bias.

Johnson and Johnson
For more than 30 years, Johnson & Johnson has been a leader in supporting the LGBTQIA+ community through its employee policies, business practices and advocacy.

The Company strives to create a workplace where LGBTQIA+ employees feel they can show up authentically — and that supports each individual and their families with inclusive policies and benefits. Recognizing the equality of all forms of families has long been a priority for Johnson & Johnson, dating back to when the company began granting domestic-partner benefits nearly 20 years ago. Today, the company offers assistance with fertility treatments as well as adoption and surrogacy to heterosexual and same-sex spouses alike.

Johnson & Johnson has more than 130,000 employees across the world and 12 Employee Resource Groups (ERGs) that help unite colleagues through their shared interests, identities, affinities and experiences. Open&Out is one of the fastest-growing ERGs at the company, with nearly 4,000 LGBTQIA+ employee and ally members across 100-plus chapters around the world.

Open&Out’s members are crucial sources of new and diverse ideas that can help the company not only build a stronger employee community overall but also enable the company to better serve diverse customers around the globe.

In 2023, Open&Out is commemorating its 30th anniversary. As part of the theme “30 Years Strong,” the group is paying homage to the efforts of thousands of employees who were pioneers in ensuring that meaningful inclusion remains at the forefront of Johnson & Johnson's company culture.

Lundbeck
For Lundbeck, supporting the LBGTQIA+ populations starts with our employees. This year, Lundbeck is launching our LBGTQIA+ employee resource group (ERG), called LuPride. LuPride offers engaging company events and content on our integrated digital channels. At Lundbeck, we understand that restoring brain health is only possible if we ensure inclusion and belonging within our organization, including those identifying as LGBTQIA+ community members.

Otsuka
At Otsuka, our commitment to the LGBTQ+ Community is driven by our DE&I vision to create an inclusive, equitable today and tomorrow for our people, patients, and communities. We know that many in the LGBTQ+ Community experience stigma, discrimination and bias in the health care system, which often leads to adverse outcomes. This is why Otsuka people work passionately every day to improve the health and well-being of LGBTQ+ patients faced with mental health, brain disease, nephrology, or neurology challenges by removing barriers to care, addressing health disparities, and ensuring equitable access to our resources, products, and clinical trials.

Pfizer
From offering enhanced employment benefits to our sponsorship of health equity initiatives and policy advocacy, we champion programs and policies that level the playing field for the LGBTQIA+ community. Our OPEN Colleague Resource Group offers mentoring as well as developmental and networking opportunities to help its members advance their careers at Pfizer. Our continued support for this community has earned us a 100 score every year since 2004 on the Human Rights Campaign Foundation Corporate Equality Index that evaluates U.S.-based businesses on their treatment of LGBTQIA+ consumers, employees, and investors.

Sage Therapeutics
At Sage, we’re dedicated to fostering a diverse and inclusive culture that enables a sense of belonging and innovative thinking. Our Business Resources Groups (BRGs) represent the unique voices, experiences, and backgrounds of employees, contributing to creating a workplace culture that is inclusive and offers networking, mentoring, and professional and personal development. SageLavender, our BRG dedicated to LGBTQIA+ Sageans, works to foster community and inclusivity through initiatives such as LGBTQIA+ speaking panels, Pride month social events, and working groups to discuss clinical trial diversity.

Sanofi 
Sanofi is a proud supporter of the LGBTQ+ community. Sanofi’s support for the community includes philanthropic donations and local volunteerism in support of LGBTQ+ non-profit organizations; a robust PRIDE Connect employee resource group with over 1000 member promoting advocacy and awareness; as well as inclusive total wellbeing and benefits programs, such as medical coverage for gender affirming care and family-building benefits.

Takeda
Takeda proudly supports our LGBTQ+ employees around the world during pride month and all year long! Takeda’s employee resource group, Take Pride, serves as a visible resource for all Takeda employees- regardless of sexual orientation or gender identity to ensure that Takeda’s LGBTQ+ employees and allies feel safe, respected, and supported. The group’s focus this year is on community impact, strengthening the talent pipeline, networking and engagement, and cultural awareness and allyship. In support of pride month’s theme the “Power of Unity”, we will be celebrating the progress that’s been made while bringing awareness to the ongoing challenges the community continues to face with programming focused on how to unite and build an inclusive community, educate allies, and drive diversity. #PowerOfUnity2023.

UCB
Thanks to the support the focus of DEI in UCB's corporate strategy and the support provided to UCB’s Employee Resource Groups (ERG), UCB has created an environment where UCB+, as the ERG supporting UCB’s LGBTQ+ employees, can emerge and have a place at the table. UCB+ has actively participated in national and local meetings, raising awareness about the unique lived experiences and challenges faced by LGBTQ+ employees. Furthermore, UCB+ was allowed to contribute to a global UCB DE&I Townhall and sit on a discussion panel with leadership to emphasize the importance of UCB+ within the ERG landscape. With UCB's backing, UCB+ marched it’s first Atlanta Pride in October 2022. Additionally, the organization is reaching out to community groups that support the LGBTQ+ community to explore volunteer opportunities and demonstrate UCB's tangible support for this community.

Andrew Powaleny

Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.

Andrew Powaleny

Author Twitter

Author LinkedIn

Bayh-Dole: The fuel for America’s innovation engine

September 2, 2026

ICYMI: Biopharmaceutical companies in America hit new investment milestone

August 14, 2026

Staffing up: Building the future biopharma workforce to keep America in the lead

June 29, 2026

World Sickle Cell Day: Recognizing the promise of gene therapy

June 19, 2026

Nearly 80 researchers advocate on Capitol Hill

June 11, 2026

America's cancer research progress is real and worth protecting

May 28, 2026

Ahead of ASCO: Cancer innovation is promising, but policy choices matter

May 26, 2026

How AI is transforming the drug innovation lifecycle

March 19, 2026

Congratulations to our 2026 Working for Cures Employee Champions

January 29, 2026

Manufacturing U.S. jobs and breakthroughs

October 6, 2025

Historic biopharmaceutical investments: A prescription for America’s future

September 29, 2025

Bringing to life the full story of biopharmaceutical innovation and investments

July 22, 2025

What to know about vaccine ingredients: Aluminum and thimerosal

June 24, 2025

Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share

June 17, 2025

PhRMA Foundation celebrates 60 years of investing in future scientific leaders

June 11, 2025

New report: Post-approval innovation delivers substantial patient benefits

June 2, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

ICYMI: PhRMA submits comments to White House on artificial intelligence

March 17, 2025

4 things to know on Rare Disease Day

February 28, 2025

Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report

February 21, 2025

New policy agenda charts solutions for a healthier America

February 20, 2025

A successful PhRMA Forum highlights our commitment to a healthier America

February 20, 2025

Guest Perspective: Prioritize Innovative Care

February 11, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

A new administration poses new opportunities for patient access

December 17, 2024

Recognizing the value of disease prevention with Dr. Len Friedland from GSK

December 12, 2024

Congratulations to our 2024 Working for Cures Employee Champions

December 11, 2024

Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.

November 13, 2024

The importance of partnership: A conversation with Takeda

October 10, 2024

New Report: Tackling chronic conditions with preventive treatment

September 30, 2024

Addressing the mounting threat of antimicrobial resistance

September 23, 2024

40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?

September 19, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

How to protect your children’s health this school year

August 22, 2024

Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers

August 1, 2024

Three things to know about the United Nations’ new HIV/AIDS report

July 31, 2024

New Report: Vaccines continue to drive improved health outcomes

July 16, 2024

The future of oncology R&D lies in policymakers’ hands

July 8, 2024

More than 60 researchers advocate on Capitol Hill

July 1, 2024

Showcasing the promise of biopharma at ASCO 2024

June 28, 2024

Alzheimer's & Brain Awareness Month: A conversation with Biogen

June 27, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eisai

June 24, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company

June 20, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

Women’s Health Month: A conversation with Astellas

May 31, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Mental Health Awareness Month: Supporting loved ones and improving mental health in America

May 28, 2024

Women’s Health Month: A conversation with Sage

May 23, 2024

The use of real-world data in drug development

May 13, 2024

New analysis: Accelerated approval pathway is changing lives in underserved communities

April 30, 2024

World Vaccine Congress: Building on vaccine success

April 1, 2024

The impact of innovative medicines: A caregiver's perspective

March 26, 2024

ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development

March 25, 2024

What new cures would mean to families

March 7, 2024

Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day

February 29, 2024

American Heart Month: A nurse’s perspective

February 27, 2024

Proposed march-in framework would chill American innovation

February 7, 2024

Three things to know about antibody drug conjugates

February 2, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

What they are saying: Experts agree that proposed march-in framework would jeopardize innovation

January 25, 2024

Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high

January 23, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

The White House continues to attack American innovation

December 15, 2023

Taking stock of obesity and its costly effects

December 8, 2023

Congratulations to our 2023 Working for Cures Employee Champions

December 6, 2023

Watch: Putting patients front and center for World AIDS Day

November 30, 2023

Misuse of march-in could stifle innovation

November 27, 2023

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

The IRA’s pill penalty threatens the future of oncology R&D

November 16, 2023

Don't close the door on rare disease research

November 13, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

Word of the Month: The Bayh-Dole Act

November 8, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot

October 18, 2023

Three things economists are saying about the Inflation Reduction Act

October 11, 2023

Celebrating Hispanic Heritage Month at PhRMA

October 11, 2023

Word of the Month: AMR

September 27, 2023

New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients

September 11, 2023

Watch: New video series spotlights advances in biopharmaceutical science

August 24, 2023

Decentralized clinical trials and the future of drug development

August 9, 2023

WTAS on reasonable pricing and public-private partnerships

August 8, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

More than 60 researchers ask Congress to support innovation

June 26, 2023

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

June 22, 2023

ASCO 2023: Protecting our progress in the fight against cancer

June 15, 2023

Reject efforts to undermine America’s R&D ecosystem

June 15, 2023

Highlights from ASCO 2023

June 8, 2023

Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics

May 30, 2023

Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation

May 11, 2023

Support for continued progress is critical for pediatric drug development

May 8, 2023

New resource underscores the importance of small molecule medicines

May 4, 2023

Policies need to address the growing threat of antimicrobial resistance

April 28, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

CMS guidance on IRA price setting process doubles down on bad policy

April 14, 2023

A guide to MedPAC’s Part B vote today

April 13, 2023

ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability

April 7, 2023

New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans

March 28, 2023

Celebrating the success of the COVID-19 vaccines, and looking to the future

March 27, 2023

IRA Impacts: Cancer treatment research and development

March 23, 2023

PhRMA submits comments to OSTP on enhancing clinical trial diversity

March 21, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

February 28, 2023

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

February 23, 2023

State policymakers can protect American innovation and help Americans live longer, healthier lives

February 9, 2023

Novel medicines approved in 2022 offer increased treatment options for patients

January 23, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

WTAS: Inflation Reduction Act already impacting R&D decisions

January 17, 2023

Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit

December 8, 2022

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

November 17, 2022

Congratulations to our 2022 Working for Cures Employee Champions

November 10, 2022

New government price setting policy threatens post-approval research

November 10, 2022

ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research

November 8, 2022

New paper: Addressing the growing crisis of mental health and substance use disorders

November 7, 2022

Protecting treatment advances for breast cancer

October 31, 2022

The law driving technology transfer and fostering innovation

October 24, 2022

Don’t take anti-innovation, activist funded academics at their word

October 18, 2022

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

October 13, 2022

Mental Illness Awareness Week – A time for reflection

October 3, 2022

New Report: Nearly 800 medicines in development to treat chronic conditions

September 29, 2022

Recognizing National Sickle Cell Awareness Month

September 23, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

August 10, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

An open letter to Congress: Stand with patients and future cures

August 4, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

August 1, 2022

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

July 29, 2022

The Senate’s latest price setting proposal will undermine: American medical innovation

July 27, 2022

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

July 18, 2022

Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

July 14, 2022

Word of the Month: Biomarkers and surrogate endpoints

July 11, 2022

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

July 7, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

Key takeaways from ASCO's annual meeting

June 10, 2022

Biopharmaceutical researchers to discuss the value of R&D with Congress

June 9, 2022

Recognizing LGBTQ+ Pride in biopharmaceutical science

June 9, 2022

Report: More than 500 medicines in development to treat disorders of the blood

May 18, 2022

Ensuring timely reauthorization of PDUFA and BsUFA

May 11, 2022

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

May 9, 2022

Spotlighting a growing mental health challenge

May 9, 2022

A conversation with Barry Greene, CEO of Sage Therapeutics

May 4, 2022

ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

April 28, 2022

Stephanie Dyson of BMS on reducing health disparities

April 27, 2022

The biopharmaceutical industry leads in helping women achieve new heights, according to IAM’s diversity 100

April 20, 2022

Report: More than 600 medicines in development for diseases affecting women

March 31, 2022

The accelerated approval pathway: Helping patients with serious or life-threatening diseases

March 17, 2022

Biopharmaceutical industry drives economic growth in all 50 states

March 14, 2022

Biopharmaceutical research and development has ushered in a decade of innovation in rare disease

February 28, 2022

4 things to know about biopharmaceutical efforts to fight cancer

February 24, 2022

What you need to know about newly authorized COVID-19 antiviral treatments

February 22, 2022

Guest post: Joining forces to combat the COVID-19 mental health crisis

February 17, 2022

PhRMA submits comments urging CMS to withdraw coverage proposal

February 11, 2022

The importance of timely PDUFA and BsUFA reauthorization

February 3, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

Protecting U.S. innovation abroad to support economic and pandemic recovery

February 1, 2022

ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients

January 26, 2022

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

January 24, 2022

New data show continued decline in death rates for cancer patients related to treatment advances

January 20, 2022

New Report: Nearly 800 new medicines in development to treat rare diseases

December 16, 2021

Recap: Our inaugural graduate summit and career expo

December 8, 2021

New report details the promise of the biopharmaceutical pipeline

December 7, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS

December 1, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

November 18, 2021

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

November 1, 2021

Guest post: Continued research and development is critical for ALS patients and families

October 25, 2021

New report shows more than 260 medicines in development to fight neurodegenerative diseases

October 12, 2021

The important role of antivirals in the fight against COVID-19

October 6, 2021

Understanding Long COVID-19

September 29, 2021

Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition

September 28, 2021

Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry

September 28, 2021

Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda

September 27, 2021

Meeting Tomorrow: Looking ahead to PDUFA VII

September 27, 2021

Industry leaders discuss the impact of the drug pricing debate

September 23, 2021

PhRMA releases 2021 industry profile

September 20, 2021

Addressing data challenges to improve health equity

September 17, 2021

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

September 8, 2021

Patients and innovators lose if the government pursues ‘march-in’

September 7, 2021

The impact of monoclonal antibodies and COVID-19 recovery

September 2, 2021

Recognizing National Immunization Awareness Month

August 31, 2021

PDUFA VII is critical for future biopharmaceutical innovation and for patients

August 23, 2021

Recognizing Hepatitis R&D on World Hepatitis Day

July 28, 2021

We Work for Health: Discovering champions, even amid challenging times

July 26, 2021

PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

July 22, 2021

3 things that support robust biopharmaceutical research and development

June 29, 2021

IP Explained: How does the U.S. patent process work?

June 24, 2021

Watch: Building trust and enhancing clinical trial diversity

June 24, 2021

Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US

June 23, 2021

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

June 22, 2021

Researchers to shine light on biopharmaceutical R&D with policymakers

June 15, 2021

How research evolves and brings new hope to patients

June 11, 2021

Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers

June 4, 2021

Creating a new patient risk paradigm in American health care

May 18, 2021